OncoMatch/Clinical Trials/NCT07061704

Oncolytic Virus in Esophageal Squamous Cell Carcinoma

Is NCT07061704 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Oncolytic Virus: Administered via intratumoral and Oncolytic Virus: Administered via intratumoral for esophageal cancer.

Phase 1/2RecruitingSichuan UniversityNCT07061704Data as of May 2026

Treatment: Oncolytic Virus: Administered via intratumoral · Oncolytic Virus: Administered via intratumoral — This clinical trial is designed to evaluate the preliminary efficacy and safety of an oncolytic virus combined with chemotherapy and an immune checkpoint inhibitor in patients with initially unresectable, locally advanced esophageal squamous cell carcinoma (ESCC). The primary endpoints are safety, surgical conversion rate and event-free survival (EFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), and quality of life (QoL). Exploratory endpoints include biomarker analyses such as single-cell sequencing.

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: antitumor chemotherapy

Received prior antitumor chemotherapy

Cannot have received: radiotherapy

Received prior radiotherapy

Cannot have received: immunotherapy

Received prior immunotherapy

Lab requirements

Blood counts

Normal major organ function

Kidney function

Normal major organ function

Liver function

Normal major organ function

Cardiac function

Normal major organ function

Normal major organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify